Vendor, Atlanta, GA
Metaclipse Therapeutics Corp.
UEI MU6JZBDZR8X1, CAGE 6BYQ1
1 award and $299,984 obligated between September 4, 2025 and August 11, 2026, 100% under full and open competition, against 55.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in NanotechnologyNAICS 541713 | $299,984 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00038Definitive Contract, September 4, 2025, Full and Open Competition After Exclusion of Sources, 55 offers | NIH NCINational Institutes of Health | SBIR Concept Award for Development of Therapeutic or Preventative Technologies for Treatment or Prevention of Pediatric Cancers And/Or Rare NAICS 541713, PSC AN12 | $299,984 |
- Places of performance
- Georgia
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 2 across 1 awards